New Vivus board appoints Zook as CEO
This article was originally published in Scrip
Executive Summary
Former AstraZeneca commercial head Anthony "Tony" Zook was appointed CEO of obesity drug maker Vivus as expected now that the Mountain View, California-based company's largest investor First Manhattan Co (FMC) controls a majority of the Vivus board of directors seats.
You may also be interested in...
Orexigen Follows Through On Warning It May Have To Liquidate
Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.